Form 4: LivaNova Director Reports Routine Share Acquisition and New RSU Grant

LivaNova PLC Director Peter M. Wilver reported the vesting of 3,416 restricted stock units, the acquisition of an equivalent number of ordinary shares, and a new grant of 4,042 restricted stock units, alongside the withholding of 410 shares for tax purposes.

Summary

• Peter M. Wilver, a Director of LivaNova PLC, reported transactions involving the company's ordinary shares and restricted stock units (RSUs) on June 15, 2025.
• 3,416 vested restricted stock units were settled, resulting in the acquisition of 3,416 ordinary shares of LivaNova PLC. These RSUs were granted under the company's 2015 Incentive Award Plan on June 15, 2024.
• Concurrently, 410 ordinary shares were disposed of at a price of $45.76 per share to satisfy tax liabilities related to the RSU vesting.
• Following these transactions, Mr. Wilver's direct beneficial ownership of ordinary shares is 6,738.
• Additionally, Mr. Wilver was granted 4,042 new restricted stock units under the 2025 Director Incentive Award Plan on June 15, 2025. These new RSUs are scheduled to vest on June 15, 2026, contingent on continued service.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, reflecting routine compensation events for a director. The vesting of RSUs and grant of new ones are standard practices and generally viewed positively as they align director interests with shareholders, though the tax-related sale is a common, neutral event.

Positives

• Acquisition of 3,416 ordinary shares through the vesting of restricted stock units, increasing direct ownership.
• Grant of 4,042 new restricted stock units, indicating continued incentive and alignment with shareholder interests.

Negatives

• Disposal of 410 ordinary shares to cover tax liabilities, reducing the net shares acquired from the RSU vesting.

Future Outlook

The grant of 4,042 new Restricted Stock Units, vesting on June 15, 2026, indicates a future incentive for the director tied to continued service.

Industry Context

This filing is a routine disclosure of insider stock transactions, common across all publicly traded companies, reflecting standard executive and director compensation practices involving equity awards. It does not provide specific insights into broader industry trends for medical technology companies like LivaNova PLC.

Comparison to Industry Standards

• This Form 4 details standard equity compensation practices for a director, including RSU vesting and new grants, which are common mechanisms used by public companies globally to align executive and director interests with shareholders.
• The specific value of shares withheld for tax ($45.76) is a market price at the time of transaction, not a comparative metric.
• No specific comparable companies or projects are mentioned in this filing.

Stakeholder Impact

• Shareholders: The vesting and grant of RSUs align the director's interests with shareholders by increasing their equity stake and providing future incentives tied to company performance. The sale of shares for tax purposes is a minor, routine event.

Next Steps

• The 4,042 new Restricted Stock Units are scheduled to vest on June 15, 2026, subject to continued service.

Key Dates

Keywords

LivaNova PLC, LIVN, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Share Ownership, Director Compensation, Equity Grant, Stock Vesting, Corporate Governance